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dasatinib have different side effect proﬁles. The aim of this
study was to investigate costs of adverse events (AEs) in
patients receiving recommended doses of nilotinib or dasatinib
for treatment of chronic and accelerated CML. METHODS:
Incidence rates of grade 3/4 AEs in CML patients treated with
nilotinib or dasatinib were obtained from clinical trial data.
Direct medical costs for non-hematological AEs and for grade 4
anemia and thrombocytopenia, and febrile neutropenia were
obtained from Ontario Case Costing Initiative (OCCI) inpatient
databases and were speciﬁc to oncology patients. Costs for
grade 3 anemia, thrombocytopenia, and non-febrile neutrope-
nia were assumed to be outpatient costs and were based on
literature and expert validation of treatment pathway and
resource utilization in the Canadian context. Multivariate sen-
sitivity analyses were conducted on costs of AEs and for an
alternative dasatinib dosing (100 mg). RESULTS: Cost of
treatment-related AEs for CML patients was highest for dasa-
tinib. Total costs for AEs associated with the accelerated phase
were higher than those associated with the chronic phase:
$19,902 versus $7,653 for dasatinib and $8,645 versus $3,790
for nilotinib, respectively. Ranking observed among treatments
for base case costs of AEs was maintained for both high and
low cost estimates, and for 100 mg dasatinib dosing, indicating
that the model was robust to variation in these parameters.
CONCLUSION: For patients resistant or intolerant to ima-
tinib, costs of dasatinib-related AEs were approximately twice
the costs of nilotinib-related AEs in both chronic and acceler-
ated phases, highlighting the importance of considering the cost
of AEs in economic evaluation of tyrosine kinase inhibitors.
Further research is needed to evaluate the impact of AEs on
health care expenditures.
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OBJECTIVES: We developed a probabilistic decision model of
cost-effectiveness for lung cancer (LC) screening with helical
computed tomography (hCT) compared with chest x-ray (CXR)
and no screening (NS) given uncertain efﬁcacy and risks of
screening in practice. METHODS: Markov model comparing NS
to CXR and hCT screening in 60-year old current smokers
screened annually until age 75 as base case using published
literature, Surveillance Epidemiology and End Results database,
and Mayo Clinic data. In the base case, we assumed stage shifts
observed with screening translate into survival beneﬁts. Sensitiv-
ity analyses evaluated cohort ages for starting and stopping
screening, screening compliance, smoking status, positive nodule
management and treatment costs. An expected value of perfect
information analysis (EVPI) was estimated to determine the value
of further research to reduce current uncertainty. RESULTS: In
the base case, CXR cost $51,245/QALY vs. NS and hCT was
dominated by CXR. The probability that CXR is cost-effective
was 94.3% at a maximum acceptable ratio of $100,000/QALY
(4.8% and 0.9% for NS and hCT, respectively). EVPI analysis
suggested that at a maximum ICER of $100,000/QALY, further
research would potentially be worth $55 million for the US
population over ten years. When it was assumed that hCT
screening did not result in any false positives necessitating
invasive surgery, hCT cost $119,571/QALY vs. CXR. CXR cost
$137,652 vs. NS for former smokers and was dominated by NS
for never smokers; hCT was dominated in both these analyses.
Results were sensitive to age at annual screening initiation and
termination. CONCLUSIONS: Assuming stage shifts observed
with LC screening translate into survival beneﬁts, hCT was, as
expected, most efﬁcacious, but also had the highest false positive
rate. The associated detrimental cost and quality of life effects
resulted in hCT being dominated by CXR (less efﬁcacious but
more speciﬁc).
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OBJECTIVE: To examine the cost-effectiveness of introducing an
HPV-16/18 prophylactic cervical cancer (CC) vaccine in a setting
of existing screening in Portugal. METHODS: A Markov cohort
simulation model was used with an annual cycle length and
which mimics the natural history of HPV infection to CC. The
analysis was undertaken from the health care system perspective.
Direct medical costs were estimated and discounted at a rate of
3%. Effect measures were: CC cases and deaths avoided, life
years saved and QALYs, discounted at a rate of 3%. The incre-
mental cost-effectiveness was estimated by comparison of the
options to be implemented with the current strategy. The analytic
horizon was lifetime where subjects enter the model at 10 years
old and are followed for 95 cycles until death. One-way sensi-
tivity analysis was conducted on the key variables. RESULTS:
Our results predicted that an HPV-16/18 vaccine targeting
12-year-old girls would be cost-effective and could reduce life-
time CC cases and mortality by 92% compared with current
screening. Vaccination was predicted to substantially reduce the
number of oncogenic HPV infections and Cervical Intraepithelial
Neoplasia cases (CIN1-3 cases). The additional cost of generat-
ing one QALY by implementing a vaccination strategy, where all
12-year-old girls are vaccinated with a vaccine showing 96.7%
efﬁcacy against HPV-16/18, was €13,810. The results were sen-
sitive to alternative assumptions about the discount rate and age
at which vaccination begins. The base-case strategy was robust to
modiﬁcations in vaccination coverage and fairly robust
to changes in both percentages of oncogenic HPV and of oppor-
tunistic screening rates. CONCLUSION: The analysis suggested
that prophylactic cervical cancer vaccination could have a sub-
stantial public health beneﬁt. A vaccine directed speciﬁcally at
reducing the incidence of oncogenic HPV types 16 and 18, during
the peak ages of infection, could be expected to be economically
attractive.
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OBJECTIVE: Determine appropriate scenarios for screening
compliance for vervical cancer in Israel. METHODS: Genera-
lised cost-effectiveness estimates of screening (PAP, HPV-DNA,
VIA at various frequencies) and/or HPV vaccination interven-
tions for cervical cancer in Israel were calculated using WHO-
CHOICE standardised methodology, utilising a state transition
population model (POPMOD) simulating Israeli population
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demographics. RESULTS: What single intervention should we
currently use? HPV vaccine (three doses, costing $120 per dose at
age 12) is not cost-effective as its cost per Quality-Adjusted-Life-
Year (QALY) is more than three times the magnitude of the GNP
per head. Adoption of a thrice a lifetime PAP screening strategy
dominates (ie: costs less and adds more QALYs) the current
strategy, which opportunistically gives PAP screens to 12.2% of
females annually. However, because of the inevitable future fall in
the HPV vaccine price, it is not recommended to abandon the
current opportunistic PAP smear strategy for a more systematic
thrice a lifetime strategy. When should the HPV vaccination be
adopted? Assuming non-waning efﬁcacy, HPV vaccinations
become cost effective when cost falls below $97 per dose, become
very cost-effective (ie: cost per QALY < per capita GNP) when
cost falls below $50 per dose and become cost-saving (ie: gains in
decreased treatment costs exceed increased screening, program
and training costs) when cost per dose falls below the $27.20
threshold. After HPV vaccination is adopted, should we still have
screening programs? Expansion of the PAP program to a penta-
annual PAP program would provide the most additional QALYs
within cost-effectiveness constraints. CONCLUSION: PAP com-
pliancy should be increased to 20.0% per annum, both before
and after the vaccination is introduced. An HPV vaccination
program should be adopted when the vaccine price drops to a
level that it becomes affordable to the Ministry of Health or falls
below $20.44 per dose, providing a cost-saving incentive to the
health insurance funds.
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OBJECTIVE: Geﬁtinib, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, is a new treatment option for
non-small cell lung cancer (NSCLC). Some studies have found
better clinical outcomes for geﬁtinib treatment in women, never-
smokers, certain mutation in the tumor EGFR gene, and patients
with adenocarcinoma and in East Asian ethnicity. However,
geﬁtinib is currently regarded as a salvage treatment rather than
a ﬁrst-line option. The objective of this study was to assess the
cost-effectiveness of geﬁtinib for ﬁrst-line treatment of the inop-
erable, chemo-naïve NSCLC patients in Taiwan. METHODS:
We developed a Markov model of the cost, quality of life, sur-
vival, and incremental cost-effectiveness of the alternative option
with geﬁtinib for ﬁrst-line treatment, as compared with current
practice of platinum-based chemotherapy regiments. Variables of
clinical effectiveness were determined from corresponding trials.
The economic analysis adopted the health care payer’s perspec-
tive, and only direct medical costs were taken into account.
RESULTS: Use of geﬁtinib for ﬁrst-line treatment had a better
mean survival than platinum-based chemotherapies (13.1 versus
11.6 months) while increasing lifetime cost. Given the base-case
assumptions, we found that geﬁtinib increased life expectancy by
1.49 months, or 0.80 quality-adjusted months, at an estimated
cost of $4,140 per treated patient, for an incremental cost-
effectiveness ratio (ICER) of $62,100 per quality-adjusted life-
year (QALY). The ICER would decrease to $48,600 per QALY
gained when such analysis was applied to a subgroup of patients
with molecular marker of EGFR exon 19 deletion or L858R
mutations while they had a signiﬁcantly longer mean survival of
20.8 months. Sensitivity analyses showed that this ICER
remained below $100,000 per QALY for all model variables.
CONCLUSION: Use of geﬁtinib for ﬁrst-line treatment has a
cost-effectiveness ratio below $50,000 per QALY gained in
advanced NSCLC patients with preferred clinical characteristics
in which a signiﬁcant extension of overall survival has been
demonstrated.
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OBJECTIVE: Currently imatinib resistant or intolerant CML
patients have minimally effective therapies available. Dasatinib
binds to the protein Bcr-Abl; it binds also to active and inactive
forms of protein, while imatinib binds only to the inactive forms.
Therefore, mutations that affect the active form can lead to
resistance to imatinib. A Markov model was built to evaluate the
long-term cost-effectiveness of dasatinib in the treatment of adult
CML patients, after resistance or intolerance to imatinib.
METHODS: The model consists of an initial within-trial period
in which best response rates observed from the clinical trials
are used. Response was deﬁned as best response of complete
hematologic response (CHR), minor cytogenetic response (CyR),
minimal CyR, partial CyR, and complete CyR. The model simu-
lates patients moving between health states using progression
probabilities derived from the literature and BMS clinical trials.
The time horizon was the lifetime of patients in the cohort,
allowing evaluation of life expectancy and lifetime costs. Brazil-
ian costs and health resource estimates were applied to the treat-
ment of the different phases of CML. RESULTS: For CML
patients in CP dasatinib provided 0.66 QALYs per patient and
the ICER was R$80,000 with an additional life expectancy of
0.98 years. In the case of AP dasatinib provided an additional life
expectancy of 3.48 years with a ICER of R$91,000. And in the
BP dasatinib provided an additional life expectancy of 1.91 years
with a ICER of R$123,000. CONCLUSION: The CE analysis
showed that dasatinib is more cost-effective in the resistant or
intolerant patients than imatinib in the three phases of CML with
increased life expectancy with quality. Though there is an incre-
mental cost associated to the treatment with dasatinib, the cost is
related to longer life expectancy and therefore expenditure of
more resources.
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OBJECTIVE: Gastric cancer is the ﬁfth most prevalent cancer
and the ﬁfth cause of cancer-related mortality in Taiwan. The
objective of this study was to access the cost-effectiveness of
capecitabine plus cisplatin (XP) vs. intravenous 5-ﬂuorouracil
plus cisplatin (FP) for the treatment of advanced and metastatic
gastric cancer (AGC) in Taiwan, from a payer’s (Bureau of
National Health Insurance [BNHI]) perspective. METHODS: A
cost-minimization analysis (CMA) was conducted by applying
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